Isotechnika appoints Colin Mallet to its Board of Directors



    EDMONTON, Feb. 7 /CNW/ - Isotechnika Inc. (TSX:ISA) announced today the
appointment of Mr. Colin Mallet to its Board of Directors. Mr. Mallet is a
professional director with extensive commercial experience in the
pharmaceutical/biotechnology industry. He has held senior executive positions
in the pharmaceutical industry in UK, Switzerland, Sweden, S.E. Asia and
Canada.
    Mr. Mallet was President and CEO of Sandoz Canada Inc. (now Novartis) for
seven years and is a past Chair of the Canadian Association of Research-Based
Pharmaceutical companies. He has served as a Pharmaceutical Business
Consultant to several major international pharmaceutical companies and has
been a director of more than a dozen biotechnology companies at various stages
of development. Mr. Mallet currently serves on the Boards of three public
biotechnology companies, Axcan Pharma Inc., MethylGene, and Migenix Inc., and
has been Chair of the Corporate Governance committees for each of these
companies. He has previously served as a Board member for such companies as
AnorMed, Cardiome Pharma Corp. and YM Biosciences Inc. He holds a B.A. (Econ.)
from Cambridge and is a graduate of both the Harvard Advanced Management
Program and the Canadian ICD Corporate Governance College.
    "I have been associated with the field of transplantation since
cyclosporin was first introduced and I am excited about the advances which
Isotechnika is making in this field," Mr. Mallet stated. "I am therefore
delighted to be joining their Board at this time."
    "We are extremely pleased that Mr. Mallet, a highly respected individual
in the pharmaceutical/biotech industry, has agreed to join our Board. This is
a very important point in the Company's history and we believe Mr. Mallet's
significant knowledge of transplantation and the healthcare sector will
benefit our efforts of advancing ISA247 through to commercialization," stated
Dr. Robert Foster, Chairman & Chief Executive Officer of Isotechnika Inc.

    About Isotechnika
    -----------------
    Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments. There is a significant unmet medical need in the
treatment of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential exceeds $2 billion annually in sales for
calcineurin inhibitors such as ISA247.
    ISA247 is currently being investigated in a Phase 2b North American trial
for the prevention of kidney graft rejection subsequent to transplantation and
a Phase 3 European/Canadian psoriasis trial.
    Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found
at www.isotechnika.com.

    
    Partnerships with Isotechnika Inc.
    ----------------------------------
    -   Roche retains an option to continue development of the transplant
        indications based on the successful completion of the ongoing
        Phase 2b kidney transplant trial.
    -   Atrium Medical Corporation has exclusive worldwide licensing
        agreement for use of ISA247 and TAFA93 with drug eluting devices for
        non-systemic treatment of vascular, cardiovascular, target vessel and
        tissue disorders.
    -   Lux Biosciences Inc. was granted worldwide rights to develop and
        commercialize ISA247 for the treatment and prophylaxis of all
        ophthalmic diseases.
    

    Forward-Looking Statements
    --------------------------
    This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements.

    %SEDAR: 00010508E




For further information:

For further information: Dr. Robert Foster, Executive Chairman,
Isotechnika Inc., (780) 487-1600 (246), (780) 484-4105 (fax),
rfoster@isotechnika.com; Stephanie Gillis-Paulgaard, Director, Corporate
Communications, Isotechnika Inc., (780) 909-4661, (780) 484-4105 (fax),
sgillis-paulgaard@isotechnika.com

Organization Profile

ISOTECHNIKA PHARMA INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890